Abstract
The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Volume: 4 Issue: 3
Author(s): Kevin Kimbro and Sabrenia Parker
Affiliation:
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Abstract: The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Export Options
About this article
Cite this article as:
Kimbro Kevin and Parker Sabrenia, Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206904
DOI https://dx.doi.org/10.2174/157489209789206904 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Biology of Cholecystokinin and Gastrin Peptides
Current Topics in Medicinal Chemistry Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Signal Transduction Abnormalities in Suicide: Focus on Phosphoinositide Signaling System
CNS & Neurological Disorders - Drug Targets The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Impact of Environmental Toxicants on Testicular Function
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances and Perspectives in Liposomes for Cutaneous Drug Delivery
Current Medicinal Chemistry Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment
Current Drug Delivery Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Ovarian Aging: Melatonin Regulation of the Cytometric and Endocrine Evolutive Pattern
Current Aging Science The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Use of Lactobacilli and their Pheromone-Based Regulatory Mechanism in Gene Expression and Drug Delivery
Current Pharmaceutical Biotechnology